A detailed history of American Century Companies Inc transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, American Century Companies Inc holds 53,990 shares of TRVI stock, worth $228,917. This represents 0.0% of its overall portfolio holdings.

Number of Shares
53,990
Previous 54,108 0.22%
Holding current value
$228,917
Previous $161,000 11.8%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$2.58 - $3.51 $304 - $414
-118 Reduced 0.22%
53,990 $180,000
Q2 2024

Aug 07, 2024

BUY
$2.44 - $3.36 $19,280 - $26,550
7,902 Added 17.1%
54,108 $161,000
Q1 2024

May 14, 2024

BUY
$1.3 - $3.7 $32,685 - $93,029
25,143 Added 119.37%
46,206 $159,000
Q4 2023

Feb 13, 2024

BUY
$1.06 - $2.05 $22,326 - $43,179
21,063 New
21,063 $28,000
Q3 2023

Nov 13, 2023

BUY
$2.11 - $2.47 $45,210 - $52,924
21,427 New
21,427 $46,000

Others Institutions Holding TRVI

About Trevi Therapeutics, Inc.


  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $247M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track American Century Companies Inc Portfolio

Follow American Century Companies Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

News

Stay updated on American Century Companies Inc with notifications on news.